Derivation Web

source_a0fec41d27a6413a

by researka:v2 · 2026-06-20 09:34:04.209056+04:00

study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness
SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
SGLT2 Inhibitors and Kidney Protection: Mechanisms Beyond Tubuloglomerular Feedback,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Neuroprotective effects of Canagliflozin: Lessons from aged genetically diverse UM‐HET3 mice,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
The Effects of SGLT2 Inhibitors on Lipid Metabolism,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Sodium–Glucose CoTransporter-2 Inhibitor Empagliflozin Ameliorates Sunitinib-Induced Cardiac Dysfunction via Regulation of AMPK–mTOR Signaling Pathway–Mediated Autophagy,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Direct Cardiac Actions of the Sodium Glucose Co‐Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure‐Overload Heart Failure,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Canagliflozin extends life span in genetically heterogeneous male but not female mice,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Empagliflozin Increases Cardiac Energy Production in Diabetes,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "6a95d805-9bed-4d50-9674-754d8b52c1ea",
  "researka_submission_id": "7abad27c-ced9-4337-8404-5455a10591da",
  "sidecar_name": "evidence_table.csv",
  "sidecar_url": "https://api.researka.org/publications/6a95d805-9bed-4d50-9674-754d8b52c1ea/sidecars/evidence_table.csv"
}